Food and Drug Administration
Center for Drug Evaluation and Research
Nonprescription
Drugs Advisory Committee (NDAC)
in joint session with the
Advisory
Committee for Reproductive Heath Drugs (ACRHD)
Hilton,
Questions to the Committee
1. Does the Actual Use
Study (AUS) demonstrate that consumers used the product as recommended in the
proposed labeling?
2. Are the AUS data
generalizable to the overall population of potential non-Rx users of Plan B?
3. Based on the AUS and
literature review, is there evidence that non-Rx availability of Plan B leads
to substitution of emergency contraception (EC) for the regular use of other
methods of contraception?
4. Do the data
demonstrate that Plan B is safe for use in the non-prescription setting?
5. Are the plans for
introduction of Plan B into the non-Rx setting adequate with respect to
consumer access and safe use? If no, what other options would you recommend?
6. Do you recommend
Plan B be switched from Rx to non-Rx status?
If yes, any
modifications to labeling or distribution?
If no, what additional information
would be required?